Oratane (isotretinoin oral): Uses, Dosage & Side Effects

What it's for (Indications)

Isotretinoin oral is primarily indicated for the treatment of severe, recalcitrant nodular acne (also known as acne conglobata or cystic acne) in adult and adolescent patients 12 years of age and older who have not responded to conventional therapies, including systemic antibiotics and topical treatments.
This includes cases where the acne is associated with a high risk of permanent scarring, significant psychological distress, or extensive involvement of the trunk.
The decision to initiate isotretinoin therapy should be made after careful consideration of the severity of the condition, the patient's response to previous treatments, and the potential for serious adverse effects, particularly its profound teratogenic potential.
It is not indicated for mild or moderate acne that can be managed effectively with less potent therapies.
Other severe forms of acne that are resistant to conventional treatment, such as acne fulminans or gram-negative folliculitis, may also be considered for isotretinoin therapy under strict medical supervision due to the significant risk of tissue damage and systemic inflammation associated with these conditions.
The goal of isotretinoin treatment is to achieve sustained remission of acne.

Dosage Information

Type	Guideline
Standard	Isotretinoin products like ABSORICA and ABSORICA LD are not interchangeable due to differing bioavailability. For ABSORICA, the recommended dosage is 0.5 to 1 mg/kg/day, given in two divided doses for 15 to 20 weeks. For ABSORICA LD, the recommended dosage is 0.4 to 0.8 mg/kg/day, given in two divided doses for 15 to 20 weeks. Adult patients with very severe disease (e.g., scarring, trunk involvement) may have their dosage increased to 2 mg/kg/day for ABSORICA (or 1.6 mg/kg/day for ABSORICA LD) in divided doses. Once-daily dosing is not recommended. If a dose is missed, it should be skipped; do not take two doses at the same time. Prior to prescribing, perform fasting lipid profiles and liver function tests.

Type

Guideline

Standard

Isotretinoin products like ABSORICA and ABSORICA LD are not interchangeable due to differing bioavailability. For ABSORICA, the recommended dosage is 0.5 to 1 mg/kg/day, given in two divided doses for 15 to 20 weeks. For ABSORICA LD, the recommended dosage is 0.4 to 0.8 mg/kg/day, given in two divided doses for 15 to 20 weeks. Adult patients with very severe disease (e.g., scarring, trunk involvement) may have their dosage increased to 2 mg/kg/day for ABSORICA (or 1.6 mg/kg/day for ABSORICA LD) in divided doses. Once-daily dosing is not recommended. If a dose is missed, it should be skipped; do not take two doses at the same time. Prior to prescribing, perform fasting lipid profiles and liver function tests.

Safety & Warnings

Common Side Effects

Common side effects include dryness and erosion of mucosa, alopecia (patch baldness), nausea, headache, drowsiness, sweating, mood swings, menstrual irregularity, myalgia (muscle pain), and arthralgia (joint pain).
More serious adverse reactions reported include disrupted liver function (hepatotoxicity), psychiatric disorders (including depression and suicidal ideation), neurological disorders (e.
g.
, Intracranial Hypertension/Pseudotumor Cerebri), serious skin reactions, pancreatitis, lipid abnormalities, inflammatory bowel disease, musculoskeletal abnormalities, ocular abnormalities (visual disturbances), hearing impairment, blood dyscrasias, and the presence of blood and protein in the urine.
Hypersensitivity reactions can also occur.

Serious Warnings

Black Box Warning: WARNING: EMBRYO-FETAL TOXICITY – CONTRAINDICATED IN PREGNANCY. Isotretinoin can cause life-threatening birth defects and is contraindicated in pregnancy. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking any amount of isotretinoin, even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining prenatally whether an exposed fetus has been affected.
Isotretinoin carries an extremely high risk of embryo-fetal toxicity and is contraindicated in pregnancy.
Females of childbearing potential must use two effective forms of contraception for at least one month prior to, during, and for one month (four weeks) after discontinuing treatment.
Monthly pregnancy tests are required before prescribing, during therapy, and one month after discontinuation.
Continuous monitoring of liver functions and enzymes, and fasting serum lipids, is essential; treatment should be discontinued in cases of large disruptions.
Patients should be monitored for signs of depression and suicidal ideation, and treatment discontinued if severe psychiatric symptoms develop.
Serious skin reactions can occur and require immediate reporting and discontinuation of treatment.
Patients should avoid dermabrasion and wax epilation due to skin fragility.
Blood donation must be avoided for one month after treatment.
Caution is advised for patients with kidney impairment, diabetes, obesity, alcoholism, dyslipidemia, hyperlipidemia, hypervitaminosis A, and skin allergies.

How it Works (Mechanism of Action)

Isotretinoin is a retinoid that inhibits sebaceous gland function and keratinization. Clinical improvement in nodular acne is associated with a reduction in sebum secretion, which is temporary and related to dose and duration. This reflects a reduction in sebaceous gland size and an inhibition of sebaceous gland differentiation. The exact mechanism of action in severe recalcitrant nodular acne is unknown.